Panobinostat is a histone deacetylase (HDAC) inhibitor. Used in combination with bortezomib and dexamethasone, it is indicated for the treatment of patients with multiple myeloma who have previously received at least 2 treatment regimens (including bortezomib and immunomodulatory agents). As a special prescription drug, extra caution is required regarding its purchase channels, medication safety, and authenticity verification.

How to Purchase Panobinostat

Overseas Purchase

Patients may choose to consult and purchase the medication at hospital pharmacies or regular drugstores in countries or regions where panobinostat has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make budgets and plans in advance before purchasing.

Purchase through Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchasing Panobinostat

Prescription and Medication Supervision

Panobinostat must be used strictly in accordance with the doctor’s advice. The standard dose is 20mg, taken orally every other day, 3 times a week (on Days 1, 3, 5, 8, 10, and 12), with a 21-day cycle. Treatment usually lasts for 8 cycles.

Doctors will adjust the dose based on the patient’s response; do not change the medication regimen without authorization.

Medication Warnings for Special Populations

Patients with Hepatic Impairment: For patients with mild hepatic impairment, the dose needs to be reduced to 15mg; for those with moderate hepatic impairment, the dose is reduced to 10mg; panobinostat is contraindicated in patients with severe hepatic impairment.

Pregnant and Lactating Women: This drug has embryo-fetal toxicity. Women of childbearing age need to take effective contraceptive measures until 1 month after stopping the drug.

Elderly Patients: Patients over 65 years old have a higher incidence of adverse reactions and require enhanced monitoring.

Management of Drug Interactions

Avoid concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin).

During the medication period, do not consume star fruit, pomegranate/pomegranate juice, or grapefruit/grapefruit juice, as these foods may affect drug metabolism.

Methods for Authenticating Panobinostat

Verification of Packaging Characteristics

10mg Specification: Size 3 light green opaque capsules, with a radial marking of "LBH10mg" in black ink on the cap, and two radial bands of black ink on the body.

15mg Specification: Size 1 orange opaque capsules, with a radial marking of "LBH15mg" in black ink on the cap, and two radial bands of black ink on the body.

20mg Specification: Size 1 red opaque capsules, with a radial marking of "LBH20mg" in black ink on the cap, and two radial bands of black ink on the body.

Verification of Drug Information

Import Drug Registration Certificate number.

Production batch number and expiration date.

Manufacturer information (Novartis Pharmaceuticals Corporation).